increasingly popular for the treatment of spinal hemangioblastomas and intramedullary spinal tumors alike. The utility of radiosurgery and image-guided systems has been further supported by case series, which continue to show favorable outcomes. 1, 5, 7, 9, 10, 17, [20] [21] [22] Furthermore, a recent systematic review surveying 10 papers that discussed radiosurgical treatment for intramedullary spinal tumors revealed that the CyberKnife (Accuray) was used in 87% of cases and afforded favorable clinical and radiological outcomes. 8 We present a large prospective cohort of spinal hemangioblastomas treated with radiosurgery.
Methods

Patients
Between 2000 and 2011, 46 spinal hemangioblastomas in 28 patients were treated with SRS at Stanford Health Care. The clinical information was maintained in an institutional review board-approved prospective database and was retrospectively reviewed. Clinical data collected included patient demographics, date of hemangioblastoma diagnosis and its location, previous treatments (e.g., neurosurgical procedures and radiotherapy), presenting symptoms, time to last follow-up, symptoms at follow-up, and radiographic evaluation at follow-up. Radiosurgery-related data included total SRS prescription dose, maximum point dose (Dmax), isodose line, fractions administered to the tumor, tumor volume, and treated volume.
stereotactic radiosurgery
All treatments were carried out using the CyberKnife image-guided robotic radiosurgery system. Patient immobilization was achieved using an Aquaplast face mask (WFR/Aquaplast) for cervical spine lesions or a vacuumset moldable Styrofoam immobilization cushion (Vac Bag, MedTech) for lesions of the thoracic or lumbar spine. Supine contrast-enhanced 1.25-mm-thick CT scans were obtained through the spinal region of interest. Contiguous axial 2.0-mm-thick stereotactic MR images were acquired with the patient in the supine position. Both CT and MR image sets were integrated into the treatment-planning workstation to delineate the tumor. The target volume and other critical structures were contoured slice by slice on the treatment-planning CT. The spinal cord was contoured at least 1 vertebral level above and below each target lesion. Treatment plans were generated with iterative inverse treatment-planning software.
Prior to radiosurgical imaging, patients with tumors caudal to C-2 and who were treated before September 2004 underwent minimally invasive surgical placement of 3-5 small stainless steel fiducial markers into the posterior elements of adjacent vertebral bodies. After September 2004, bony anatomy alone was used for target localization with the Xsight skeletal structure tracking system (Accuray). The process of real-time imaging acquisition and dynamic targeting has been described previously. 
Follow-Up Monitoring
Patients underwent follow-up with clinical examinations at around 3 and 6 months after treatment. Patients living outside the immediate area were followed remotely by their referring physician, and progress reports as well as follow-up imaging studies were forwarded to Stanford for evaluation. Follow-up imaging studies were obtained every 3-6 months. Radiographic evaluation and clinical judgment of tumor stability, progression, regression, or radiation necrosis were made by treating clinician (radiation oncologist and/or neurosurgeon). This categorization of treatment outcomes based on radiographical and clinical evidence reflects what was ultimately put into practice and what will be most generalizable to other clinicians in a practice scenario. The actuarial local control rates were calculated using the Kaplan-Meier method. Statistical analysis was performed using the Python SciPy and lifelines packages.
results
Cohort Characteristics
The cohort of patients consisted of 14 men and 14 women, with a median age of 43.5 years (range 19-85 years) at the time of radiosurgery (Table 1) . Fourteen (50%) of these patients also had VHL disease. The mean number of tumors per patient was 1.64. Twenty patients had undergone previous neurosurgical operations related to hemangioblastoma resection, and 12 patients had previously received radiotherapy (Table 2) . Presenting symptoms were classified as pure motor, pure sensory, mixed, or asymptomatic (4 motor, 19 sensory, 5 mixed, and 1 asymptomatic). 
radiographic outcomes
Nine patients with 12 tumors were lost to follow-up. One patient with 4 tumors (Patient 9) had successful follow-up for 1 tumor, but follow-up for the other 3 tumors was lost. Including the latter patient and the 1 tumor with follow-up (19 patients with 31) tumors, the mean followup was 54.3 months (range 3-157 months) (Supplemental Table 2 ). Actuarial local control rates at 1, 3, and 5 years were 96.1%, 92.3%, and 92.3%, respectively (Fig. 1) .
If only patients with more than 2 years of follow-up were analyzed (11 patients with 23 lesions), actuarial local control rates at 36 and 60 months were both 100%. Among the 7 spinal lesions with less than 2 years of follow-up imaging studies, 2 showed regression of tumor volume, 3 showed radiographic stability, and 2 showed radiographic progression. For the 23 spinal lesions with more than 2 years of follow-up, 3 lesions decreased in size, whereas 20 lesions remained unchanged in size.
effect of vhl Disease on Cohort Characteristics
In our cohort, patients with VHL disease had a mean age of 38.8 years and non-VHL patients had a mean age of 53.1 years (p = 0.00001). VHL status did not seem to affect radiosurgery treatment parameters such as the prescription dose and isodose line. The mean tumor size of non-VHL tumors was 8.27 cm 3 , whereas for VHL tumors the mean tumor size was 0.53 cm 3 (p = 0.04) ( Table 3 ). This can be attributed to the fact that patients with VHL were monitored more closely, and thus lesions are detected earlier for intervention. This finding is consistent with data from other series. 
Clinical outcomes
Clinical evaluation follow-up was available for 16 tumors in 13 patients. Thirteen (81.2%) of these tumors in 10 patients had an associated improvement in symptoms, whereas 3 tumors in 3 patients showed no improvement or worsening of symptoms. However, 2 of the patients in whom symptoms did not improve had VHL disease and had additional tumor burden such as cerebellar and/or additional spinal cord lesions. No complications or adverse radiation events (AREs) related to SRS were observed after treatment or at subsequent follow-up intervals.
Discussion
This study details the prospective long-term outcomes of treatment of a large cohort of spinal hemangioblastomas treated via SRS at a single institution. In our treated cohort of 46 spinal hemangioblastomas in 28 patients, we report local control rates at 1, 3, and 5 years of 96.1%, 92.3%, and 92.3%, respectively, with a mean follow-up of 54.3 months. Of treated tumors with clinical follow-up, 81.1% demonstrated an improvement in symptoms, and there were no reported complications or AREs related to SRS. We have significantly improved control rates compared with our prior published intuitional experience of all hemagioblastomas (16 of which were spinal lesions) that had a median follow-up of 69 months and local control rates at 36 and 60 months of 85% and 82%, respectively. 14 Our results are comparable to or exceed those of similar recent studies of SRS treatment of spinal hemangioblastomas and also that of intracranial hemangioblastomas. A series of 9 patients with 20 spinal hemangioblastomas underwent image-guided linear accelerator (LINAC)-based SRS treatment and had favorable results. The estimated 4-year survival and solid local tumor control were 90% and 95%, respectively. 21 Another study examined CyberKnife treatment for a variety of benign spinal tumors including hemangioblastomas, neurogenic tumors, and meningiomas. In this series of 20 patients with 30 tumors, 57% of lesions regressed, while 33% of lesions were un- changed in size at a mean follow-up of 35.6 months. 3 In a recent, large international, multicenter study addressing the treatment of intracranial hemangioblastomas, Kano et al. reported that at a mean of 9.5 years of follow-up, the overall survival after SRS treatment was 94% at 3 years, 90% at 5 years, and 74% at 10 years. 9 Of the 335 hemangioblastomas treated that were associated with VHL disease, 134 (40%) decreased in size and 79 (43%) remained stable. Twenty-six (8%) VHL-associated tumors and 31 (16%) sporadic tumors progressed. Actuarial local control rates at 3, 5, and 10 years were 92%, 89%, and 79% respectively. A summary of other key radiosurgical studies addressing exclusively hemangioblastomas is presented in Table 4 .
Complications
Complications related to SRS treatment of spinal hemangioblastomas are rare, and worsening symptoms following treatment tend to be associated with additional intracranial or other spinal tumor burden seen most commonly in patients with VHL. No complications or adverse events were observed in our cohort and nearly 20% of patients with available clinical follow-up data in our cohort experienced worsening symptoms related to progression of disease or additional tumor burden. To minimize the risks of postoperative complications, an extensive preoperative workup is recommended. Diagnostic neuroimaging (e.g., MRI) of the brain and spinal cord is crucial, and laboratory studies are needed to determine a patient's VHL status. When adverse events related to treatment are observed, they are typically delayed and occur after treatment. The risk of AREs such as radiation necrosis is positively correlated to the dose and volume of the tumor treated. 13 Patients who present with preexisting edema around their tumor(s) may not be ideal candidates for radiosurgery, as treatment may worsen edema and exacerbate neurological symptoms. Overall, AREs are uncommon, manifesting in 0%-20% of patients treated with frame-based or LINACbased SRS (Table 4) .
Considerations for Patients with vhl Disease
Previous studies have shown that VHL disease can be diagnosed in more than 30% of patients with newly discovered hemangioblastomas.
11 Although VHL-associated lesions are detected earlier due to closer monitoring, Kano et al. recommends that small asymptomatic lesions be observed until radiographic progression or manifestation of clinical symptoms. 9 However, there is considerable controversy regarding whether to treat asymptomatic lesions, as natural history studies have suggested that VHL-associated lesions have a quiescent phase and show a biphasic development pattern. Studies such as the one by Hanakita et al. advocate for the prompt treatment of newly discovered VHL-associated lesions as the benefits of treatment outweighs the risks of the lesion enlarging or causing neurological decline. 7 Therefore, it is important to assess the indications and timing of treatment on a per-patient basis considering the patient's VHL status and the risk/benefit ratio of SRS. In our study, nearly all patients treated had symptomatic spinal lesions, including all patients with VHL, and 81% experienced an improvement in symptoms with no reported complications or adverse events. Thus, SRS treatment of symptomatic spinal hemangioblastomas in patients with VHL is a safe and effective option for tumor control and symptom management.
limitations of the series
Long-term follow-up is always essential to establish the efficacy and safety of SRS, especially for benign tumors where the reporting of short-term (< 5 years) control rates does not necessarily translate to long-term remission. For example, in a series of 44 intracranial hemangioblastomas with a mean follow-up of 8.5 years, Asthagiri and colleagues reported local control rates of 91% and 51% at 2 and 10 years, respectively. The authors of that study cautioned that evidence of early radiographic regression and/ or stability may not reflect the final outcome. A large number of the patients in this series have also received prior radiotherapy; therefore, it is not possible to determine the overall radiation dose when treating in or near the prior radiation field. Furthermore, because half of the patients in this series have VHL disease, outcomes can be skewed by various comorbid tumors these patients may have such as renal cell carcinoma, pancreatic neuroendocrine tumors, and multiple hemangioblastomas in both the spinal cord and posterior fossa.
Due to the rareness of radiographic progression in our series, we were unable to calculate statistically significant factors associated with tumor progression. Other studies have reported that younger age, female sex, smaller lesions, and the absence of a cystic component of the tumor were factors that were associated with better tumor control. 9 
Conclusions
Stereotactic radiosurgery represents a safe, noninvasive treatment option, especially for VHL patients, in the armamentarium of multidisciplinary treatment of spinal hemangioblastomas. Our results demonstrate that SRS allows for excellent local control and symptomatic management of spinal hemangioblastomas in both VHL and sporadic lesions with an optimal safety profile. This study is consistent with and supplements prior reports of radiosurgical treatment for hemangioblastomas in that SRS is associated with an optimal local tumor control rate, low risk of adverse events and complications, and can be used to treat spinal cord lesions that pose high risk for resection. 
